This study investigated the efficacy of Toxoplasma GRA16, which binds to herpes virus-associated ubiquitin-specific protease (HAUSP), in anticancer treatment, and whether the expression of GRA16 in genetically modified hepatocellular carcinoma (HCC) cells (GRA16-p53-wild HepG2 and GRA16-p53-null Hep3B) regulates PTEN because alterations in phosphatase and tensin homologue (PTEN) and p53 are vital in liver carcinogenesis and the abnormal p53 gene appears in HCC. For this purpose, we established the GRA16 cell lines using the pBABE retrovirus system, assessed the detailed mechanism of PTEN regulation in vitro and established the anticancer effect in xenograft mice. Our study showed that cell proliferation, antiapoptotic factors, p-AKT/AKT ratio, cell migration and invasive activity were decreased in GRA16-stable HepG2 cells. Conversely, the apoptotic factors PTEN and p53 and apoptotic cells were elevated in GRA16-stable HepG2 cells but not in Hep3B cells. The change in MDM2 was inconspicuous in both HepG2 and Hep3B; however, the PTEN level was remarkably elevated in HepG2 but not in Hep3B. HAUSP-bound GRA16 preferentially increased p53 stabilization by the nuclear localization of PTEN rather than MDM2-dependent mechanisms. These molecular changes appeared to correlate with the decreased tumour mass in GRA16-stable-HepG2 cell-xenograft nude mice.
| INTRODUC TI ON
Ubiquitin-specific peptidases 7/herpes virus-associated ubiquitin-specific protease (USP7/HAUSP) is a ubiquitin-specific protease in human cells that deubiquitinates MDM2 (an E3 ligase), thereby destabilizing p53. [1] [2] [3] HAUSP and USP7 are synonymous, and USP7/HAUSP (known as HAUSP) deubiquitinates the tumour-suppressor phosphatase and tensin homologue (PTEN; deleted in chromosome 10), 1, 4, 5 favouring its localization from the nucleus to the cytoplasm and limiting its transcriptional activity, eventually decreasing p53 transcription. 1, [4] [5] [6] Thus, HAUSP plays a crucial role in cell proliferation and differentiation by deubiquitinating MDM2 and PTEN; HAUSP suppression is vital for anticancer therapeutic intervention, simultaneously focusing on HAUSP as a candidate druggable target. [1] [2] [3] [4] [5] [6] Herpes virus-associated ubiquitin-specific protease is overexpressed in various human cancer types, including prostate cancer, multiple myeloma tumours, neuroblastoma, epithelial ovarian cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma (HCC) and lymphocytic leukaemia. [1] [2] [3] [6] [7] [8] Conversely, the negative regulation of HAUSP exhibits a crucial clinical significance for estimating the prognosis of tumour suppression. 5, 7 Thus, identification of HAUSP inhibitors is imperative for the therapeutic intervention of cancer. Based on the findings of a recent study, 9 the authors probed whether the properties of GRA16 recognized as a new HAUSP inhibitor could be available for anticancer intervention because the precise mechanism of GRA16 in inducing an anticancer effect remains unclear to date.
Toxoplasma gondii (T gondii)
is an intracellular parasite that infects multiple organs and tissues in acute infection and the brain in chronic infection 9, 10 and regulates the host immunity for its survival during infection. 10, 11 Briefly, the immunomodulatory activities of T gondii are mediated by infection as well as several T gondii-specific molecules such as rhoptry proteins (ROP), dense granule proteins (GRA), T gondii profilin-like protein (TgPLP) and the lysate antigenic proteins. 9, 10 Thus, our objective was to determine the intermediate events between HAUSP inhibition and p53 stabilization and also the anticancer effect. In particular, p53 transcriptional activity is often disrupted in HCC by highly expressed HAUSP; moreover, the expression of nuclear PTEN decreases in patients with advancedstage HCC. 5, 7, 17, 18 Thus, HCC forms an appropriate model for our study;
indeed, it has been known that HCC is one of the 10 most common cancer types worldwide with no ideal treatment.
17
Thus, this study aimed to investigate transcriptional gene expressions associated with PTEN and subsequent apoptosis after HAUSP inhibition by GRA16. Furthermore, it investigated the characteristics of molecular networks primarily associated with nuclear PTEN changes between HAUSP and p53 in GRA16-stable cells.
| MATERIAL S AND ME THODS

| Cell culture
We purchased HepG2 and Hep3B cells, human liver cancer cell lines, from the Korean Cell Line Bank (Seoul, Korea) and cultured 
| Cell proliferation
A total of 5 × 10 3 cells were seeded on a 96-well plate and incubated for 2, 4 and 6 days to assess the cytotoxicity of cells that were divided into experimental groups (control, vector, GRA16) in HepG2 and Hep3B cells. Cell viability at each incubation time was assessed using the Cell Counting Kit (CCK-8; Dojindo, Kumamoto, Japan) and measured in terms of optical density at 451 nm using a microplate reader (Thermo 
| Real-time PCR
Real-time PCR was performed to target genes using the CFX96 RealTime PCR Detection System (Bio-Rad Laboratories, Hercules, CA) and SYBR Green I detection chemistry (Bio-Rad Laboratories). Primer sequences are presented in Table 1 . The data were analysed using the Bio-Rad CFX manager software ver 3.1 (Bio-Rad Laboratories). 
| Western blotting
Cells were cultured in a 6-well plate with complete DMEM medium for 6 days, and total proteins were extracted from cells using the M-PER 
| Immunofluorescence for the GRA16 expression and PTEN nuclear localization
Immunofluorescence images of cells were obtained after immunostaining with HA-Tag Ab (Elabscience) and anti-PTEN Ab (Santa Cruz Biotechnology) to investigate GRA16 expression in HepG2-and Hep3B-GRA16 cells and the nuclear localization of PTEN. The immunostained cells were observed using fluorescent microscopy (Leica DMI6000 B).
| Cell cycle analysis
HepG2 and Hep3B cells with and without GRA16 were seeded at 5 × 10 5 cells/well in a 6-well plate for 6 days and stained with propidium iodide (PI). Results were analysed by flow cytometry using 
| Cell apoptosis assays using flow cytometry
| Wound healing assay
HepG2 and Hep3B cells with and without GRA16 were seeded at 
| Transwell migration/invasion assay
The migration and invasion ability of cells were assessed using the Matrigel-coated Transwell cell culture chambers (8-μm pore size;
Millipore, Billerica, MA, USA). Briefly, 700-μL complete DMEM medium was added to the lower chamber in a 24-well plate. Then, cells 
| Ethics statement
All animal experiments were approved by the Institutional Animal Care and Use Committee in Seoul National University (SNU-170717-2), and animals were maintained in the facility following standards of the Animal Protection Act and the Laboratory Animal Act in Korea. All experiments were conducted according to global standards such as those of AAALAC, and all efforts were made to ensure minimal animal suffering (SNUIBC-R180523-1). 
| Cancer cell xenograft and tumour production in GRA16 stable cell lines
| Statistical analysis
All statistical analyses were performed using the GraphPad Prism 5 software (GraphPad, La Jolla, CA, USA). Data are presented as mean ± standard deviation (SD) of three independent experiments, each performed in triplicates. One-way analysis of variance (ANOVA) was performed followed by the Tukey's multiple comparison test to assess the differences between the experimental groups. Two-way ANOVA followed by the Bonferroni's post hoc comparisons test was used to assess differences between the experimental groups.
P < 0.05 was considered statistically significant.
| RE SULTS
| Changes in the cell proliferation and total cell counts after establishing a GRA16-expressing stable cell line for HepG2 and Hep3B
A stable cell line expressing the GRA16 protein for HepG2 and Hep3B, which are p53-wild-and p53-null type, respectively, as human HCC cells was established to determine the role of GRA16 as an HAUSP inhibitor in cancer cells ( Figure 1 ). All experimental groups were divided into control (no transfection), vector (transfected with pBABE vector) and GRA16 (transfected with pBABE-GRA16 vector).
We confirmed GRA16 expression in the stable cell line by intracellular GRA16 expression using green fluorescent protein (GFP)-immunostaining ( Figure 1A ) and co-immunoprecipitation (co-IP)
assay results between GRA16 and HAUSP ( Figure 1B ). As shown in Figure 1A , GRA16 was stably expressed in cells of both GRA16-stable HepG2 and Hep3B. In particular, the GRA16 protein was present in the GRA16-HAUSP complex in GRA16-stable cells (HepG2 and Hep3B) ( Figure 1B ). These findings confirmed the establishment of GRA16-expressing stable cell lines and that GRA16 is presented by binding to HAUSP intracellularly. After transfections, cell proliferation and total cell counts in the control and vector groups increased gradually during 6 days with no differences observed in both HepG2
and Hep3B ( Figure 1C,D) . However, the cell count of GRA16-stable HepG2 cells had significantly decreased with a significant decrease in cell proliferation in comparison to the control and vector groups (P < 0.05; Figure 1C -a and C-b), whereas cell proliferation of GRA16-stable Hep3B cells increased continuously, with no difference in the total cell counts in the control and vector groups ( Figure 1C ).
Although the reduction in the total cell number during the 6-day cell culture was apparent in GRA16-stable HepG2 cells, it was not observed in GRA16-stable Hep3B cells ( Figure 1D -a and D-b). Table 2 presents these findings in detail.
| Protein expressions of PTEN and p53 as well
| An increase in the nuclear localization of PTEN in GRA16-stable-HepG2 cells
| Differences in inductions of apoptosis and p53-related apoptotic factors between GRA16-stable-HepG2 and -Hep3B cells
To investigate p53-dependent cell apoptosis in GRA16-stable For the apoptosis related with p53 in GRA16-stable HepG2 cell, we validated mRNA expressions for apoptotic (Foxo3a, BAX and P21) and antiapoptotic factors (Bcl-2, Survivin and MDM2) associated with the p53 function ( Figure 5C ). As anticipated, the mRNA levels of apoptotic factors (Foxo3a, BAX and P21) in GRA16-stable HepG2 cells were significantly increased in comparison to both control and vector groups (P < 0.05; Figure 5C ). In contrast, the mRNA levels of antiapoptotic factors (Bcl-2 and Survivin) were decreased in GRA16-stable HepG2 cells (P < 0.05; Figure 5C ).
However, the increase in apoptotic factors was not observed in Hep3B cells ( Figure 5C ). Meanwhile, antiapoptotic factors exhibited no change in GRA16-stable Hep3B cells as well as the control and vector groups ( Figure 5C ). These findings implied that the role of GRA16 as a HASUP inhibitor was exhibited in p53-wild-type cells. and C-a). In addition, we assessed the mRNA levels of MMP2 and PTK2 (important cell migration factors), which can be increased by AKT phosphorylation and cell mobility factor, which is inhibited by PTEN respectively ( Figure 6A-c and B-c) . In HepG2 cells, the presence of GRA16 significantly reduced cell mobility at 24
and 48 hours after incubation in comparison to the control and vector groups (P < 0.05; Figure 6A-b) . In addition, the decreased cell mobility suggests that the wounded area was not reduced (Figure 6A-a) . However, in Hep3B, the wounded area (%) after scratching was covered in the same degree among the control, vector and GRA16 groups, indicating no effect of GRA16 ( Figure 6B 
| Tumour reduction in xenograft mice
| D ISCUSS I ON
The inhibition of USP (or HAUSP) has been reported as an anticancer drug target. 1 The action of HAUSP is highly specific for substrates is worth investigating HCC suppression using a HAUSP inhibitor. [1] [2] [3] 6 Typically, GRA proteins of T gondii secreted from parasites reside in the parasitophorous vacuole and play a role in the intracellular survival and replication of parasites. 13 Of these, GRA16 migrates to the nucleus and participates in the regulation of the p53 oncogene signalling pathway. 13 We assessed whether an anticancer effect could be induced by using the HAUSP-binding effect of GRA16 in HCC, and, moreover, the underlying mechanisms inducing p53 stabilization after HAUSP inhibition. As some human cancer types, including HCC, exhibit an abnormal p53 gene or have disrupted p53 gene activation pathways, the effect of GRA16 should be evaluated in conditions with and without the p53 gene. 17 Thus, in our study, we developed genetically modified GRA16-stable cancer cells for p53-wild-type HepG2 and p53-null-type Hep3B, and examined the binding between GRA16 and HAUSP within cells using the co-IP.
However, Hep3B cells did not exhibit any changes in the levels of Conversely, other studies reported that the tumour-suppressor PTEN directly interacted with p53 through the increase of endogenous p53 by deubiquitination and acetylation of p53 in an AKT-independent manner in hereditary cancer. 6, 21 Other factors inducing apoptosis of Hep3B in in vitro experiments using HepG2 and Hep3B
were under the following situation by which p21, p27, p73 and Bax/ Bcl-2 were increased by the action of an MDM2 antagonist or by which AKT inhibition was observed by notch1 overexpression, 22, 23 indicating that the precise mechanisms should be determined by the type of HAUSP inhibitor and the target substrate for the HAUSP inhibitor.
The p53 protein cooperates with PTEN and could be an essential blockage in the development of mammary tumours 6 ; thus, we can comprehend that the therapeutic efficiency of anticancer agents strongly depends on their detailed mechanisms to trigger apoptosis in targeted cancer cells. 24 As p53 plays a pivotal role in regulating tumour apoptosis, our study elucidated the prominence of the p53-dependent mechanism on the anti-HCC effect of GRA16. In HCC tumours, down-regulation of the nuclear PTEN is an essential step in hepatocarcinogenesis. 5, 19, 20 As revealed in this study, PTEN levels 
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